Form 10-K Moderna, Inc. For: Dec 31

Go back to Form 10-K Moderna, Inc. For: Dec 31

Moderna (MRNA) downgraded as HSBC skeptical on medium term INT Phase 3 data readouts

February 26, 2024 9:33 AM EST

HSBC analysts cut Moderna (NASDAQ: MRNA) to Reduce from Hold in a note Monday, raising the price target to $86 from $75 per share.

The firm said Moderna's outlook for 2024 is underpinned by prospects for its COVID-19 vaccine revenue and RSV launch. They note there are two... More